Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2015  |  Volume : 11  |  Issue : 4  |  Page : 904-910

Chelerythrine delayed tumor growth and increased survival duration of Dalton's lymphoma bearing BALB/c H 2d mice by activation of NK cells in vivo


Department of Zoology, Faculty of Science, Banaras Hindu University, Varanasi, Uttar Pradesh, India

Correspondence Address:
Arbind Acharya
Department of Zoology, Faculty of Science, Banaras Hindu University, Varanasi - 221 005, Uttar Pradesh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0973-1482.143342

Rights and Permissions

Aim: The aims of the present investigation were to evaluate the antitumor effect of chelerythrine (CHE) on in vivo growth and survival duration of BALB/c (H 2d ) mice bearing Dalton's lymphoma (DL) and enhanced function of tumor associated NK cells (TANK cells). Materials and Methods: BALB/c (H 2d ) mice at 8-10 weeks of age of either sex were used. Increasing concentration of CHE (1.25, 2.5, and 5.0 mg/kg), staurosporine (0.625, 1.0, 1.5, and 2.0 mg/kg) and cyclophosphamide (25, 50, 100, and 200 mg/kg) were administered intraperitoneally and tumor regression and survival duration of tumor bearing host were determined, and thereafter expression of NKG2D and NKG2A on TANK cells were detected. Results: Our results show that treatment with 2.5 mg/kg of CHE results in a significant reduction in mean tumor volume and increased survival duration of DL bearing BALB/c (H 2d ) mice when compared to control. Activating receptor NKG2D on TANK cells were observed upregulated in contrast to inhibitory receptor NKG2A. Conclusions: CHE reduced mean tumor volume and increased survival duration of DL bearing BALB/c (H 2d ) mice. Increased expression of activating receptor NKG2D on TANK cells results in recovery of immunosuppression during tumor progression. Therefore, CHE could be a potential anticancer therapeutic agent that may be used to replace chemo-radio-therapy in future.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2988    
    Printed34    
    Emailed0    
    PDF Downloaded106    
    Comments [Add]    

Recommend this journal